# Akebia Therapeutics Q2 financial and clinical results

> Live situation record from CLSTR: https://clstr.news/situations/akebia-therapeutics-q2-financial-and-clinical-results
> Updated: 2026-08-08T18:27:37.000Z. Sources: 4. Developments: 2.

Akebia Therapeutics reported second-quarter results characterized by a significant divergence in product performance. Revenue for its anemia drug, Vafseo, grew 60% year-over-year to $21.3 million, supported by a 41% sequential increase in active patients. Conversely, total company revenue fell 21.5% to $49.1 million, largely due to Auryxia sales dropping from $47.2 million to $25.5 million amid pricing pressure and generic competition.

The company also shared results from its VOICE trial involving 2,116 patients. The study met predefined stopping criteria, showing a statistically significant 10% reduction in the composite endpoint of all-cause mortality and hospitalization. CEO John Butler stated the results “confirmed the drug’s efficacy and supported continued commercial expansion.”

## Timeline

### 2026-08-08: Axsome Therapeutics reports 46% revenue growth in Q2 2026

Axsome Therapeutics reported Q2 2026 net product revenue of $218.4 million, up 46% year over year, driven by strong AUVELITY sales despite a quarterly net loss of $51.3 million.

3 sources. https://clstr.news/cluster/axsome-therapeutics-reports-46-revenue-growth-in-q2-2026

### 2026-08-05: Akebia Therapeutics reports Vafseo growth and Auryxia sales decline in Q2

Akebia Therapeutics posted Q2 growth for Vafseo, with revenue up 60% to $21.3 M and 10,500 patients, while Auryxia sales fell 46% to $25.5 M. An interim VOICE trial showed mortality and hospitalization cuts, sp

2 sources. https://clstr.news/cluster/akebia-therapeutics-reports-vafseo-growth-and-auryxia-sales-decline-in-q2

---
Cite as: Akebia Therapeutics Q2 financial and clinical results. CLSTR, https://clstr.news/situations/akebia-therapeutics-q2-financial-and-clinical-results